Lead Product(s) : GE8820
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Novo Holdings
Deal Size : $130.0 million
Deal Type : Series B Financing
GlycoEra AG Raises $130 Million To Advance Protein Degraders for Autoimmune Diseases
Details : The financing aims to advance the clinical development of company's lead product GE8820, which is being evaluated for the autoimmune diseases such as pemphigus, primary membranous nephropathy etc.
Product Name : GE8820
Product Type : Antibody
Upfront Cash : Undisclosed
May 27, 2025
Lead Product(s) : GE8820
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Novo Holdings
Deal Size : $130.0 million
Deal Type : Series B Financing
Lead Product(s) : Exo-101
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Exogenus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Exogenus Therapeutics Partners with Lonza to Develop GMP Process for Exo-101 Manufacturing
Details : The collaboration aims to develop Exo-101, Exogenus’ exosome-based lead candidate. It is derived from immunologically privileged cells from umbilical cord blood, being evaluating for fibrosis.
Product Name : Exo-101
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : Exo-101
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Exogenus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : miCAR19
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antion Develops Safety-Enhanced Off-The-Shelf CAR T-Cells For Autoimmune Disease
Details : miCAR19, is an anti-CD19 CAR T-cell &gene therapy candidate, which is currently being evaluated for the treatment of B-cell driven autoimmune diseases.
Product Name : miCAR19
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : miCAR19
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Forty51 Ventures
Deal Size : $3.5 million
Deal Type : Financing
Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies
Details : The capital will be used to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to uniquely modulate multi-lineage immune cell functions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Forty51 Ventures
Deal Size : $3.5 million
Deal Type : Financing
Lead Product(s) : Cladribine
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
Details : The company entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a company focused on rare neuroinflammatory diseases. Acquisition provides opportunity to develop cladribine in Myasthenia Gravis and Neuromyelitis Optica ...
Product Name : Mavenclad
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 20, 2021
Lead Product(s) : Cladribine
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : MP1032
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032
Details : The results confirm the very good safety profile of MetrioPharm's lead compound MP1032. They allow for long-term clinical studies in chronic indications to be conducted in the future.
Product Name : MP1032
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2021
Lead Product(s) : MP1032
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OCi mAb
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Eurostars
Deal Size : Undisclosed
Deal Type : Funding
Details : The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : OCi mAb
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Eurostars
Deal Size : Undisclosed
Deal Type : Funding